Jacobson Pharma Beheer
Beheer criteriumcontroles 1/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Derek Sum
Algemeen directeur
HK$20.8m
Totale compensatie
| Percentage CEO-salaris | 19.6% |
| Dienstverband CEO | 8.8yrs |
| Eigendom CEO | 60.2% |
| Management gemiddelde ambtstermijn | geen gegevens |
| Gemiddelde ambtstermijn bestuur | 8.6yrs |
Recente managementupdates
Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21
Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Recent updates
There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump
Nov 22Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now
Aug 21Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues
Dec 21Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025
Nov 27These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well
Jun 20Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Nov 28Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268
Sep 25Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?
Sep 16Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year
Jul 28Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's
Jul 14Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?
Feb 09Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012
Nov 29Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015
Sep 24Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year
Sep 16Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares
Feb 03
A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)
Jan 24Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden
Jan 11Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?
Dec 27Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?
Dec 12Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years
Dec 03Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | HK$253m |
| Jun 30 2024 | n/a | n/a | HK$220m |
| Mar 31 2024 | HK$21m | HK$4m | HK$186m |
| Dec 31 2023 | n/a | n/a | HK$221m |
| Sep 30 2023 | n/a | n/a | HK$217m |
| Jun 30 2023 | n/a | n/a | HK$234m |
| Mar 31 2023 | HK$14m | HK$3m | HK$175m |
| Dec 31 2022 | n/a | n/a | HK$207m |
| Sep 30 2022 | n/a | n/a | HK$203m |
| Jun 30 2022 | n/a | n/a | HK$190m |
| Mar 31 2022 | HK$5m | HK$3m | HK$178m |
| Dec 31 2021 | n/a | n/a | HK$166m |
| Sep 30 2021 | n/a | n/a | HK$154m |
| Jun 30 2021 | n/a | n/a | HK$164m |
| Mar 31 2021 | HK$5m | HK$4m | HK$174m |
| Dec 31 2020 | n/a | n/a | HK$183m |
| Sep 30 2020 | n/a | n/a | HK$191m |
| Jun 30 2020 | n/a | n/a | HK$203m |
| Mar 31 2020 | HK$5m | HK$4m | HK$214m |
| Sep 30 2019 | n/a | n/a | HK$273m |
| Jun 30 2019 | n/a | n/a | HK$259m |
| Mar 31 2019 | HK$5m | HK$4m | HK$245m |
| Dec 31 2018 | n/a | n/a | HK$235m |
| Sep 30 2018 | n/a | n/a | HK$219m |
| Jun 30 2018 | n/a | n/a | HK$211m |
| Mar 31 2018 | HK$6m | HK$4m | HK$202m |
Compensatie versus markt: De totale vergoeding ($USD 2.67M ) Derek } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Hong Kong markt ($USD 349.51K ).
Compensatie versus inkomsten: De vergoeding van Derek is het afgelopen jaar met meer dan 20% gestegen.
CEO
Derek Sum (61 yo)
8.8yrs
Tenure
HK$20,779,000
Compensatie
Mr. Kwong Yip Sum, also known as Derek, is Non-Executive Chairman of the Board at JBM (Healthcare) Limited since September 22, 2020. He joined the company and its subsidiaries September 22, 2020. With exte...
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 8.8yrs | HK$20.78m | 60.18% HK$ 956.0m | |
| VP of Administration & Executive Director | 7.8yrs | HK$3.18m | 0.42% HK$ 6.7m | |
| Executive Director | 8.6yrs | HK$6.77m | 2.04% HK$ 32.4m | |
| Independent Non-Executive Director | 8.6yrs | HK$230.00k | geen gegevens | |
| Independent Non-Executive Director | 8.3yrs | HK$230.00k | geen gegevens | |
| Member of Scientific Advisory Committee | 8.6yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Committee | 8.6yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Committee | 8.6yrs | geen gegevens | geen gegevens | |
| Non-Executive Director & Member of Scientific Advisory Committee | 8.6yrs | HK$230.00k | geen gegevens | |
| Independent Non-Executive Director | 8.3yrs | HK$230.00k | 0.030% HK$ 481.3k |
8.6yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 2633 wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.6 jaar).